

ASX ANNOUNCEMENT

6 November 2025

First Two Patients Enrolled in the WiSE-UP Post-Approval Study

The WiSE-UP post-approval study enrolls commercially-treated patients to gather real-world evidence for the WiSE left ventricular endocardial pacing system.

Key Highlights:

- The first two patients have now been enrolled in the WiSE-UP post-approval study by Dr Devi Nair from St Bernards Heart & Vascular Center, Arkansas
- The EBR-sponsored study will evaluate real-world outcomes for heart failure patients receiving the FDA-approved WiSE® System for cardiac resynchronization therapy (CRT)
- The study will follow more than 300 patients across 50 US centers over a five-year period, and will generate both short- and long-term performance metrics

Sunnyvale, California; 6 November 2025: EBR Systems, Inc., (ASX: “EBR”, “EBR Systems”, or the “Company”) developer of the world’s only wireless cardiac pacing device for heart failure, is pleased to announce that the first patient has now been enrolled in the WiSE® System Utilization & Performance (WiSE-UP) Study.

The first two patients in the WiSE-UP Study were treated at the St Bernards Heart & Vascular Center, Arkansas, on Tuesday 4 November 2025 (US time) by globally-respected electrophysiologist Dr Devi Nair. This achievement marks a significant milestone in the advancement of CRT for heart failure patients.

The WiSE-UP Study, sponsored by EBR Systems, is a prospective observational study designed to evaluate real-world outcomes for heart failure patients receiving the FDA-approved WiSE System utilising left ventricular endocardial pacing (LVEP) for CRT. The study will follow more than 300 commercial patients across 50 centers over a five-year period and will generate both short- and long-term performance metrics.

*“It was an honour to lead the team performing the first WiSE System implant as part of the WiSE-UP Study,” said **Devi Nair, MD, FACC, FHRS, Electrophysiologist at St. Bernards Heart & Vascular Center.** “Our entire team is proud to contribute to this important study, which we believe will further demonstrate the benefits of left ventricular endocardial pacing for patients with heart failure. We look forward to continuing our collaboration with EBR Systems as we work together to advance innovation in cardiac resynchronization therapy and improve patient outcomes.”*

Niraj Varma, MD, PhD, FRCP, Professor of Medicine at the Cleveland Clinic and the National Principal Investigator for the study said: *“The launch of the WiSE-UP Study marks an exciting moment in cardiac resynchronization therapy. This study will evaluate the application of left ventricular endocardial pacing in real world practice, capture important clinical outcomes over time, and assess sustained therapeutic impact of the WiSE System. I am proud to lead this initiative that will continue to develop the standards of care for heart failure patients.”*

ENDS

This announcement has been authorised for release by the Routine Disclosure Committee, a Committee of the Board.

For more information, please contact:

Company

Andrew Shute
Chief Corporate Development Officer
P: +44 7730 691421
E: info@ebrsystemsinc.com

Investor Relations

Julia Maguire
The Capital Network
P: +61 2 8999 3699
E: julia@thecapitalnetwork.com.au

EBR SYSTEMS, INC. (ARBN 654 147 127)

480 Oakmead Parkway, Sunnyvale CA 94085 USA T: +1 408 720 1906 W: <https://ebrsystemsinc.com/>

About EBR Systems

Silicon Valley-based EBR Systems (ASX: EBR) is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing. The patented proprietary Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads, historically the major source of complications, effectiveness and reliability issues in cardiac rhythm disease management. The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). Future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications.

EBR Systems' WiSE Technology

EBR Systems' WiSE technology is the world's only wireless, endocardial (inside the heart) pacing system in clinical use for stimulating the heart's left ventricle. This has long been a goal of cardiac pacing companies since internal stimulation of the left ventricle is thought to be a potentially superior, more anatomically correct pacing location. WiSE technology enables cardiac pacing of the left ventricle with a novel cardiac implant that is roughly the size of a large grain of rice. The need for a pacing wire on the outside of the heart's left ventricle – and the attendant problems – are potentially eliminated. WiSE is an investigational device in most markets and is currently only available for sale in the US.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties, contingencies and other factors, many of which are beyond the Company's control, subject to change without notice and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory applications and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. EBR does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. EBR may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Foreign Ownership Restriction

EBR's CHES Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of EBR's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.